Markup of Fifteen Bills

Health Care Costs and Drug PricingHouse Energy and Commerce Subcommittee on Health · 2026-06-25 · 119th Congress
The House Energy and Commerce Subcommittee on Health met to mark up fifteen bills covering hospital and insurer price transparency, Medicare Advantage reporting requirements, community health center funding, and scheduling of xylazine and nitazenes as controlled substances. Begins at 0:27:36
Transcript
Highlights

Title

Subcommittee advances 15 health transparency and opioid bills

Purpose

The House Energy and Commerce Subcommittee on Health met to mark up fifteen bills covering hospital and insurer price transparency, Medicare Advantage reporting requirements, community health center funding, and scheduling of xylazine and nitazenes as controlled substances. Chairman Griffith and Ranking Member DeGette both noted the markup builds on the panel's prior hearings on health care affordability and price transparency, while disagreeing over the pace of the process and the omission of a provider-ownership transparency bill. Begins at0:27:36

Who spoke

Chairman Morgan Griffith (R-VA)0:27:36: Opened by describing the markup's goal of lowering health care costs via transparency bills building on Trump administration price-transparency rules0:27:36; later spoke in support of nearly every bill, including the Combating Illicit Xylazine Act0:41:46 and the Lower Cost, More Transparency Act0:41:19.

Rep. Diana DeGette (D-CO), Subcommittee Ranking Member0:32:12: Criticized the rushed process and lack of CBO scores0:33:26, objected to two bills carrying prison penalties0:33:56, and pressed for a private-equity hospital-ownership transparency bill left out of the markup0:34:12; later offered and withdrew a xylazine-scheduling amendment0:42:360:46:27 and an ownership-transparency amendment to H.R. 93931:31:451:34:37.

Rep. Brett Guthrie (R-KY), Full Committee Chairman0:35:29: Praised the committee's work on HALT Fentanyl and SUPPORT Act reauthorization0:35:58 and previewed the xylazine/nitazenes and price-transparency bills0:36:26; spoke on H.R. 9393 as co-author0:54:02.

Rep. Frank Pallone (D-NJ), Full Committee Ranking Member0:37:17: Argued Republicans' "big, ugly bill" cut health care by $1 trillion and that expiring ACA credits will double or triple premiums0:37:37; opposed H.R. 7970's class-wide nitazene scheduling as bypassing science-based review0:56:35 and H.R. 9390's wall-posted prices as confusing1:51:47; offered a technical amendment to H.R. 52432:14:38.

Rep. Kim Schrier (D-WA)0:46:54: Supported the xylazine bill from a medical perspective, noting Narcan doesn't reverse xylazine sedation0:47:18; later described MA plans' 50 million prior-authorization requests versus 625,000 under traditional Medicare in 20241:57:071:57:29, and supported broker-compensation transparency2:21:15.

Rep. Gus Bilirakis (R-FL)0:48:35: Co-led the xylazine bill with Reps. Panetta, Fitzgerald, Pappas and Ross, describing traffickers' use of xylazine as a cutting agent0:49:05.

Clerk0:41:46: Read each bill number and title into the record throughout the markup, e.g., H.R. 12660:41:46 and H.R. 93931:13:47.

Rep. Sean Casten or unnamed member ("gentleman from Colorado") — not distinctly identified separately from DeGette's amendment discussion.

Rep. Kat Cammack / unidentified "gentleman from California" (HERO Act sponsor)1:03:32: Introduced the HERO Act, citing UCLA Health data that 22 adolescents aged 14–18 died weekly from overdoses in 20221:04:04.

Rep. Diana Harshbarger (R-TN), Vice Chair1:06:35: Spoke on her Nutrition Education and Chronic Disease Prevention in Community Health Centers Act, drawing on her career as a pharmacist1:06:35; later supported the Premium Transparency Act, H.R. 93971:39:45.

Rep. (unnamed, "gentlelady from Colorado" continuing) on H.R. 82011:11:32: DeGette praised Rep. Lee's community health center behavioral health bill, citing an HRSA estimate that 7.7 million health center patients need mental health services and 5.2 million need substance use treatment1:12:23.

Rep. John James (R-MI)1:17:40: Said he would support the transparency package but argued it doesn't go far enough, pushing his "Patients Deserve Price Tags" bill and pledging to force an amendment vote the following week1:18:101:20:21.

Rep. Greg Landsman (D-OH)1:20:21: Offered and withdrew an amendment to H.R. 9393 requiring senior-official attestation of hospital price data accuracy1:21:201:24:26.

Rep. Earl "Buddy" Carter (R-GA)1:24:55: Offered and withdrew an amendment on vision benefit manager (VBM) transparency and lab choice, alongside Rep. Yvette Clarke1:25:221:31:15.

Rep. Nanette Barragán (D-CA)1:35:07: Described her own surprise medical bill from GW Hospital1:35:33 and a constituent, Lauren in Colorado, billed $64,000 after ankle surgery before it was reduced to a $250 copay1:36:02; urged itemized-bill and ownership-transparency requirements1:37:58.

Rep. (unnamed member speaking on H.R. 9397 amendment) — Chairman Griffith acknowledged DeGette's point that ACA already requires medical-loss-ratio disclosure1:42:22.

Rep. (unnamed, Iowa) Mariannette Miller-Meeks (R-IA)1:49:27: Introduced the Prices on the Wall Act requiring posted cash prices1:49:27; later described a delayed MRI diagnosis of a brain tumor caused by prior-authorization delays1:59:24.

Rep. David Joyce (R-PA)1:54:33: Spoke for the Improving Seniors' Timely Access to Care Act, noting over 290 House co-sponsors1:54:52; later explained the Medicare Advantage Cost Transparency Act with DeGette2:06:59.

Rep. Lizzie Fletcher (D-TX)2:01:32: Said Houston-area physicians report prior authorization delays and burnout2:01:58.

Rep. Troy Carter (D-LA)2:03:57: Noted Louisiana has one of the highest MA enrollment rates and supported the seniors' timely access bill2:04:22.

Rep. Alexandria Ocasio-Cortez (D-NY)2:18:20: Explained her Transparency in Medicare Advantage Steering Act, citing a Brown University study finding agents/brokers received $10 billion from MA insurers for enrollments in 20222:19:38.

Key moments

DeGette said two of the day's bills would result in Americans being imprisoned and argued the markup was moving "haphazardly" without full CBO scores or agency technical assistance0:33:260:33:56.

DeGette's amendment to reclassify xylazine from Schedule III to Schedule V (misdemeanor vs. felony penalties) was withdrawn after Griffith pledged to "follow the science" before full committee0:43:010:46:040:46:27.

Pallone opposed H.R. 7970's permanent class-wide Schedule I listing of nitazenes, citing GAO findings that Schedule I status obstructs research and citing opposition from the Leadership Conference on Civil and Human Rights, Drug Policy Alliance, and Vera Institute0:57:030:59:10; the bill passed on a voice vote1:00:30.

Rep. James publicly challenged colleagues to back his "Patients Deserve Price Tags" bill instead of the weaker Lower Cost, More Transparency Act, calling election-year politics "utter bullcrap" and pledging to force a vote the next week1:18:101:20:21.

DeGette noted all four witnesses at the panel's prior hearing supported hospital/physician-ownership transparency, including the American Enterprise Institute, yet that bill (introduced by Reps. Schakowsky and Bilirakis) was left out of the markup0:34:121:32:06.

Rep. Carter's vision-benefit-manager transparency amendment described two VBMs covering nearly 200 million Americans that also manufacture eyewear and own optical labs and retail locations, and was withdrawn after Griffith promised further work before full committee1:26:371:31:15.

Schrier cited that Medicare Advantage beneficiaries generated over 50 million prior-authorization requests in 2024 versus about 625,000 for traditional Medicare beneficiaries, despite roughly equal enrollment1:57:071:57:29.

Pallone's amendment in the nature of a substitute to H.R. 5243 cited MedPAC findings that MA payments will run 14% higher per beneficiary in 2026, totaling $76 billion in overpayments, and $1.2 trillion over ten years if the trend continues; it was adopted by voice vote2:15:342:16:022:17:22.

Ocasio-Cortez said a Brown University study found MA insurers paid agents and brokers roughly $10 billion in 2022 to steer enrollees into specific plans, funded by taxpayer dollars, and that researchers believe the figure is likely an underestimate2:19:382:19:57.

Miller-Meeks recounted a patient whose brain tumor diagnosis was delayed roughly six months due to a prior-authorization denial for an MRI, illustrating support for H.R. 35141:59:242:00:22.

All fifteen bills were forwarded to the full committee by voice vote, with H.R. 5243 amended and several members (DeGette, Landsman, Carter) withdrawing amendments after receiving assurances of continued bipartisan negotiation ahead of full committee markup1:30:222:23:20.

Metadata

CommitteeHouse Energy and Commerce Subcommittee on Health
Chamber / CongressHouse · 119th Congress
Date2026-06-25
TypeMarkup
Witnesses
(none listed in event metadata)
Videoyoutube
Transcript269 caption blocks · 18,706 words · 2:23:45 runtime
EventCongress.gov 119424